长效双磷酸盐类药物联合钙剂治疗原发性骨质疏松症的效果  

Effect of Long-acting Bisphosphonates Combined with Calcium in the Treatment of Primary Osteoporosis

作　　者：康静[1] Kang Jing(Hohhot First Hospital,Hohhot 010031,Inner Mongolia,China)

机构地区：[1]呼和浩特市第一医院,内蒙古自治区呼和浩特010031

出　　处：《中外医药研究》2023年第11期39-41,共3页JOURNAL OF CHINESE AND FOREIGN MEDICINE AND PHARMACY RESEARCH

摘　　要：目的:分析原发性骨质疏松症患者使用长效双磷酸盐类药物联合钙剂治疗的临床效果。方法:选取2020年3月—2022年3月呼和浩特市第一医院收治的原发性骨质疏松症患者68例为研究对象,根据随机数字表法分为常规组(34例,采用钙剂治疗)和观察组(34例,采用长效双磷酸盐类药物联合钙剂治疗)。比较两组患者治疗效果、骨密度、骨代谢指标、骨钙素水平、血清炎性因子水平、不良反应发生率。结果:观察组治疗总有效率高于常规组,差异有统计学意义(P<0.05);治疗后,观察组腰椎正位L2~4、股骨颈、总髋部、股骨粗隆骨密度均高于常规组,差异有统计学意义(P<0.05);治疗后,观察组甲状腺旁素、碱性磷酸酶及骨特异性碱性磷酸酶水平均低于常规组,骨钙素水平高于常规组,差异有统计学意义(P<0.05);观察组白细胞介素-6、白细胞介素-10、肿瘤坏死因子水平均低于常规组,差异有统计学意义(P<0.05);两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:长效双磷酸盐类药物联合钙剂治疗原发性骨质疏松症临床效果显著,可改善患者骨密度、骨代谢指标、骨钙素水平、血清炎性因子水平,不会显著增加不良反应。Objective:To analyze the clinical effect of long-acting bisphosphonates combined with calcium in the treatment of primary osteoporosis.Methods:A total of sixty-eight patients with primary osteoporosis admitted to Hohhot First Hospital from March 2020 to March 2022 were studied,and were divided into the conventional group(34 cases,treated with calcium)and the observation group(34 cases,treated with long-acting bisphosphonates combined with calcium)according to random number table method.The therapeutic effect,bone mineral density,bone metabolism index,osteocalcin level,serum inflammatory factor level and incidence of adverse reactions were compared between the two groups.Results:The total effective rate of observation group was higher than that of conventional group,and the difference was statistically significant(P<0.05);After treatment,BMD of lumbar spine L2~4,femoral neck,total hip and femoral trochanter in observation group was higher than that in conventional group,with statistical significance(P<0.05);After treatment,the levels of parathyroid,alkaline phosphatase and bone-specific alkaline phosphatase in observation group were lower than those in conventional group,and the levels of osteocalcin were higher than those in conventional group,with statistical significance(P<0.05);The levels of interleukin-6,interleukin-10 and tumor necrosis factor in observation group were lower than those in conventional group,and the difference was statistically significant(P<0.05);There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Long-acting bisphosphonates combined with calcium in the treatment of primary osteoporosis have significant clinical effects,which can improve bone mineral density,bone metabolism indexes,osteocalcin levels and serum inflammatory factors,without significantly increasing adverse reactions.

关 键 词：长效双磷酸盐类药物 钙剂 骨质疏松症 

分 类 号：R58[医药卫生—内分泌]